{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:52:03Z","timestamp":1783032723420,"version":"3.54.6"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/mnm.0b013e3282f3d03e","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T12:57:53Z","timestamp":1236257873000},"page":"283-290","source":"Crossref","is-referenced-by-count":21,"title":["Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide"],"prefix":"10.1097","volume":"29","author":[{"given":"Raffaella","family":"Barone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phan","family":"Walrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelf","family":"Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry K.","family":"Kvols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210212","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/bc9702258","article-title":"Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo","volume":"9","author":"Akizawa","year":"1998","journal-title":"Bioconjug Chem"},{"key":"R2-13-20210212","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue","volume":"67","author":"Hammond","year":"1993","journal-title":"Br J Cancer"},{"key":"R3-13-20210212","first-page":"1388","article-title":"Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo","volume":"37","author":"de Jong","year":"1996","journal-title":"J Nucl Med"},{"key":"R4-13-20210212","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487) \u2013 A phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-13-20210212","article-title":"Radiation Protection. Nonstochastic Effects of Ionizing Radiation","year":"1991"},{"key":"R6-13-20210212","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0301-472X(01)00772-X","article-title":"Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells","volume":"30","author":"Oomen","year":"2002","journal-title":"Exp Hematol"},{"key":"R7-13-20210212","first-page":"S232","article-title":"Red marrow toxicity after therapy with radiolabeled somatostatin analogues: a possible role of plasma proteins","volume":"30","author":"Barone","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-13-20210212","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R9-13-20210212","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"de Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R10-13-20210212","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"R11-13-20210212","first-page":"368","article-title":"Yttrium-90 and indium-111 labeling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy","volume":"24","author":"de Jong","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"R12-13-20210212","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<406::AID-IJC14>3.0.CO;2-6","article-title":"Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy","volume":"75","author":"de Jong","year":"1998","journal-title":"Int J Cancer"},{"key":"R13-13-20210212","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s002590100628","article-title":"Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide","volume":"28","author":"F\u00f6rster","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R14-13-20210212","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotide","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q J Nucl Med"},{"key":"R15-13-20210212","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new case of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R16-13-20210212","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","article-title":"End-stage renal disease after treatment with 90Y-DOTATOC","volume":"28","author":"Cybulla","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R17-13-20210212","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1053-4296(00)80049-1","article-title":"Internal dosimetry for systemic radiation therapy","volume":"10","author":"Fisher","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"R18-13-20210212","first-page":"213","article-title":"Bone marrow dosimetry and toxicity for radioimmunotherapy","volume":"3","author":"Siegel","year":"1990","journal-title":"Antibody Immunoconj Radiopharm"},{"key":"R19-13-20210212","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004728-199401000-00023","article-title":"The ECAT EXACT HR: performance of a new high-resolution positron scanner","volume":"18","author":"Wienhard","year":"1994","journal-title":"J Comput Assist Tomogr"},{"key":"R20-13-20210212","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1109\/42.363108","article-title":"Accelerated image reconstruction using ordered subsets of projection data","volume":"13","author":"Hudson","year":"1994","journal-title":"IEEE Trans Med Imaging"},{"key":"R21-13-20210212","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-002-1068-y","article-title":"Quantification in PET using isotopes emitting prompt single gammas: application to yttrium-86","volume":"30","author":"Walrand","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-13-20210212","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/BF01254478","article-title":"A non-negative fast multiplicative algorithm in 3D scatter-compensated SPET reconstruction","volume":"23","author":"Walrand","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"R23-13-20210212","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1365-2141.1995.tb08411.x","article-title":"Interpretation of measured red cell mass and plasma volume in adults. Expert panel on radionuclides of the international council for standardization in haematology","volume":"89","author":"Pearson","year":"1995","journal-title":"Br J Haematol"},{"key":"R24-13-20210212","article-title":"Specific Absorbed Fractions of Energy At Various Ages From Internal Photons Sources","author":"Cristy","year":"1987"},{"key":"R25-13-20210212","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004032-200002000-00009","article-title":"Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions","volume":"78","author":"Eckerman","year":"2000","journal-title":"Health Phys"},{"key":"R26-13-20210212","first-page":"538","article-title":"MIRDOSE: personal computer software for internal dose assessment in nuclear medicine","volume":"37","author":"Stabin","year":"1996","journal-title":"J Nucl Med"},{"key":"R27-13-20210212","first-page":"149","article-title":"Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes","volume":"41","author":"Stabin","year":"2000","journal-title":"J Nucl Med"},{"key":"R28-13-20210212","first-page":"492","article-title":"Contribution to red marrow absorbed dose from the total body activity: a correction to the MIRD method","volume":"42","author":"Stabin","year":"2001","journal-title":"J Nucl Med"},{"key":"R29-13-20210212","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/028418601750444141","article-title":"Low-energy electron emitters for targeted radiotherapy of small tumours","volume":"40","author":"Bernhardt","year":"2001","journal-title":"Acta Oncol"},{"key":"R30-13-20210212","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-004-1561-6","article-title":"Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours","volume":"31","author":"Helisch","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R31-13-20210212","first-page":"7","article-title":"Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide","volume":"36","author":"Forssell-Aronsson","year":"1995","journal-title":"J Nucl Med"},{"key":"R32-13-20210212","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implication for internal radiotherapy with 90Y-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"R33-13-20210212","first-page":"3031s","article-title":"Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger\/Conversion electron-, or \u03b1-emitters","volume":"5","author":"Behr","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R34-13-20210212","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/108497803322287718","article-title":"Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?","volume":"18","author":"Konijnenberg","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"R35-13-20210212","first-page":"1","article-title":"Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"R36-13-20210212","first-page":"111","article-title":"Tumor dosimetry based on PET 86Y-DOTA-Tyr3-octreotide (SMT486) and CT scans predicts tumor response to 90Y-SMT 487 (Octreother)","volume":"41","author":"Jonard","year":"2000","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006231-200803000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:44:44Z","timestamp":1618037084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-200803000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e3282f3d03e","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}